Partnering in pediatrics

Alexion Pharmaceuticals Inc. is hoping that its research collaboration with Cincinnati Children's Hospital Medical Center will help the biotech build out a rare disease pipeline that currently is dominated by a single molecule-Soliris eculizumab. The deal is Alexion's first collaboration with a clinical center and complements its pipeline-building efforts with biotechs and academia.

For CCHMC, the deal brings the first infusion of corporate dollars into its two-year-old innovation fund...